佐力药业11月17日获融资买入2013.53万元，融资余额5.68亿元

Core Insights - Zhaoli Pharmaceutical experienced a 2.16% decline in stock price on November 17, with a trading volume of 164 million yuan [1] - The company reported a financing net buy of -617,200 yuan on the same day, indicating a higher level of financing activity compared to the past year [1] - As of September 30, Zhaoli Pharmaceutical achieved a revenue of 2.28 billion yuan, reflecting a year-on-year growth of 11.48% [2] Financing and Trading Activity - On November 17, Zhaoli Pharmaceutical had a financing buy amount of 20.14 million yuan and a financing repayment of 20.75 million yuan, resulting in a net financing outflow [1] - The total financing and securities balance reached 570 million yuan, accounting for 4.71% of the circulating market value, which is above the 60th percentile of the past year [1] - The company had a securities lending balance of 1.68 million yuan, with a lending volume of 97,400 shares, indicating a high level of short selling activity [1] Shareholder and Profitability Information - As of September 30, the number of shareholders increased by 7.31% to 41,400, while the average circulating shares per person decreased by 6.82% [2] - The company reported a net profit attributable to shareholders of 510 million yuan for the first nine months of 2025, marking a 21% increase year-on-year [2] - Zhaoli Pharmaceutical has distributed a total of 1.442 billion yuan in dividends since its A-share listing, with 942 million yuan distributed in the last three years [3] Institutional Holdings - As of September 30, 2025, the eighth largest circulating shareholder is Innovation Drug, holding 6.85 million shares, an increase of 280,700 shares from the previous period [3] - The tenth largest circulating shareholder is Southern CSI 1000 ETF, holding 6.42 million shares, which is a decrease of 58,800 shares from the previous period [3] - The fund Zhongou Responsible Investment Mixed A has exited the list of the top ten circulating shareholders [3]